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Abstract
Tumour-specific splicing is known to contribute to cancer progression. In the case of the L1 cell adhesion molecule (L1CAM),
which is expressed in many human tumours and often linked to bad prognosis, alternative splicing results in a full-length form
(FL-L1CAM) and a splice variant lacking exons 2 and 27 (SV-L1CAM). It has not been elucidated so far whether SV-L1CAM,
classically considered as tumour-associated, or whether FL-L1CAM is the metastasis-promoting isoform. Here, we show that
both variants were expressed in human ovarian carcinoma and that exposure of tumour cells to pro-metastatic factors led to
an exclusive increase of FL-L1CAM expression. Selective overexpression of one isoform in different tumour cells revealed that
only FL-L1CAM promoted experimental lung and/or liver metastasis in mice. In addition, metastasis formation upon up-
regulation of FL-L1CAM correlated with increased invasive potential and elevated Matrix metalloproteinase (MMP)-2 and -9
expression and activity in vitro as well as enhanced gelatinolytic activity in vivo. In conclusion, we identified FL-L1CAM as the
metastasis-promoting isoform, thereby exemplifying that high expression of a so-called tumour-associated variant, here SV-
L1CAM, is not per se equivalent to a decisive role of this isoform in tumour progression.
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Introduction
The L1 cell adhesion molecule (L1CAM), a member of the
immunoglobulin-like superfamily of cell adhesion molecules [1],
has been shown to be expressed in different isoforms arising
through alternative splicing of its mRNA [2]. Alternative splicing
of mRNAs is a fine-tuned regulatory mechanism of gene
expression during ontogenesis [3]. Over the last years, it has
become evident that alternative splicing is frequently deregulated
in malignant tumours [4,5]. Consequently, the expression profile
of the various protein isoforms is often different from normal
tissues [6][4]. Importantly, splice variants can exert different [7][5]
or even opposite [8][6] functions in comparison to their full-length
counterparts. Nevertheless, the specific impact of alternative
splicing products, including those of L1CAM, on tumour
progression has not been fully elucidated so far.
Alternative splicing of the L1CAM mRNA results in a full-
length form (FL-L1CAM) and an evolutionary highly conserved
splice variant (SV-L1CAM), lacking exons 2 and 27 [9]. The FL-
L1CAM variant consists of six immunoglobulin-like domains (Ig1-
6), five fibronectin type III repeats, and a short cytoplasmic tail.
The SV-L1CAM variant exhibits alterations in the molecular
structure N-terminal of the Ig1 region and in the cytoplasmic tail
as compared to the full-length L1CAM molecule. In specific,
expression of the exon 2 peptide sequence comprising only five
amino acids affects homophilic and heterophilic binding to neural
ligands [10,11] which are important for growth-promotion of
neural cells [12]. The cytoplasmic sequence encoded by exon 27 is
a YRSLE motif which is necessary for clathrin-dependent
endocytosis and for regulation of L1CAM density at the cell
surface [13]. Indeed, internalization of L1CAM was shown to be
important for downstream signaling [14]. Moreover, src-mediated
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critical regulatory point of L1CAM-mediated adhesion and
intracellular signaling [15].
With regard to tumour pathology, overexpression of L1CAM is
detected in a variety of cancers and associated with tumour growth
and metastasis [16,17,18]. Consequently, elevated levels of
L1CAM often indicate bad prognosis for cancer patients
[19,20,21,22]. Furthermore, L1CAM has been proposed as a
promising therapeutic target since treatment with anti-L1CAM
antibodies has been shown to exhibit significant anti-metastatic
effects [23,24,25]. Importantly, in none of the previous studies
about the contribution of L1CAM to tumour progression, the
specific roles of FL-L1CAM and SV-L1CAM have been
distinguished. This lack of evidence might be due to the general
assumption that FL-L1CAM expression was restricted to neuronal
tissues [26], whereas SV-L1CAM was detected in non-neuronal
tissues including tumours and lymphocytes [27,28,29].
In the present study, we revised this axiom by demonstrating
that FL-L1CAM and SV-L1CAM mRNAs are both expressed in
benign ovarian tumours and both increased during progression of
human ovarian carcinomas. Furthermore, incubation of different
cancer cells with recombinant Hepatocyte growth factor (recHGF)
or Transforming growth factor-b1 (recTGF-b1), respectively, both
known to promote metastasis [30,31], exclusively increased the
expression of FL-L1CAM. We further elucidated that overexpres-
sion of FL-L1CAM but not of the splice variant SV-L1CAM
conferred increased metastatic potential to tumour cells of three
different entities. We showed that elevated expression of FL-
L1CAM triggered experimental liver and/or lung metastasis of a
human ovarian carcinoma cell line (SKOV3ip-lacZ), representing
an epithelial solid tumour, of a human fibrosarcoma cell line
(HT1080lacZ-K15), representing a mesenchymal solid tumour,
and of a murine T-lymphoma cell line (L-CI.5s), representing a
haematological malignancy. FL-L1CAM-associated tumour pro-
gression was accompanied by increased invasive potential and
elevated expression and activity of the Matrix metalloproteinases
(MMP) -2 and -9, both known to promote metastasis [32]. Taken
together, we characterized FL-L1CAM and not the so-called
tumour-associated splice variant as the metastasis-promoting
isoform of L1CAM.
Results
Expression of both, FL-L1CAM and SV-L1CAM, correlated
with progression of human ovarian carcinoma
To assess whether FL-L1CAM, SV-L1CAM, or both were
expressed in tissue samples from cancer patients, we determined
their mRNA levels by qRT-PCR in benign and malignant human
ovarian tumour samples of different FIGO stages and ovarian
cancer peritoneal metastases. The data show that FL-L1CAM and
SV-L1CAM mRNAs are both expressed in benign ovarian
tumours and both increased during progression of human ovarian
carcinomas and were highest in ovarian carcinoma peritoneal
metastases (Fig. 1A and B).
L1CAM splicing was deregulated in favour of FL-L1CAM
expression in ovarian and colorectal carcinoma cells
upon exposure to pro-metastatic factors
Next, we wanted to determine whether the relative amount of
splicing products of L1CAM could be modified by exposure to
known pro-metastatic factors. Therefore, we incubated SKO-
V3ip-lacZ human ovarian carcinoma and HCT-116 human
colorectal carcinoma cells with TGF-b1 or HGF, respectively. In
both cell lines, incubation with the respective pro-metastatic
factor led to an increase of FL-L1CAM-mRNA levels, while the
expression of SV-L1CAM remained unaltered (Fig. 2A and B),
suggesting that the FL-L1CAM variant had an impact on tumour
progression.
FL-L1CAM but not SV-L1CAM promoted metastasis of
human fibrosarcoma cells
In order to investigate a possible metastasis-promoting role of
FL-L1CAM, we specifically and stably overexpressed FL-L1CAM
or SV-L1CAM in lacZ-tagged HT1080 human fibrosarcoma cells
(HT1080lacZ-K15). As HT1080lacZ-K15 cells do not endogen-
eously express L1CAM (Fig. 3A), we were able to evaluate the
impact of FL-L1CAM and SV-L1CAM on metastasis formation
without interference through expression of the other isoform.
Overexpression was confirmed by Western Blot analysis using an
isoform-unspecific antibody (Fig. 3A). Overexpression of neither
L1CAM variant influenced tumour cell proliferation (Fig. 3B).
Experimental lung metastasis of HT1080lacZ-K15 overexpressing
FL-L1CAM was increased compared to the control, whereas
overexpression of the SV-L1CAM variant was less efficient in
inducing lung metastasis (Fig. 3C and D). This visual observation
was even more prominent when we performed quantification of
metastatic burden by qRT-PCR of human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a marker of the human
tumor cells (Fig. 3E). In the liver this metastasis-inducing effect of
FL-L1CAM overexpression was even markedly superior to SV-
L1CAM overexpression, which actually did not promote exper-
imental liver metastasis at all (Fig. 3F).
FL-L1CAM but not SV-L1CAM also promoted metastasis
of human ovarian carcinoma and murine T-lymphoma
cells
To assess whether the metastasis-promoting effect of FL-
L1CAM was cell line-specific, we specifically and stably overex-
pressed one of the two L1CAM isoforms in lacZ-tagged human
SKOV3ip-lacZ ovarian carcinoma and L-CI.5s T-lymphoma cells.
Overexpression of L1CAM variants in both cell lines was
confirmed by Western Blot analysis (Figure S1A and S2A).
Isoform-transduced SKOV3ip-lacZ and L-CI.5s cell lines did not
show any difference in cell proliferation as compared to the empty
vector controls (Figure S1B and S2B). Lung metastasis of
SKOV3ip-lacZ (Fig. 4A and B) and liver metastasis of L-CI.5s
cells (Fig. 4C and D) were significantly increased only when cells
overexpressed the FL-L1CAM variant.
FL-L1CAM overexpression correlated with increased
invasive capacity as well as gelatinase expression and
activity
In a previous study, L1CAM has been shown to promote
invasion of tumour cells [33]. Therefore, we aimed to determine
whether overexpression of one of the L1CAM isoforms specifically
enhanced the invasive potential of a tumour cell line. We chose the
HT1080 model as this cell line does not express endogenous
L1CAM, so that the transduced isoforms did not interfere with
endogenous L1CAM expression. Overexpression of FL-L1CAM
but not of SV-L1CAM led to a significant increase in the invasive
potential of this cell line in vitro (Fig. 5A). As Matrix metallopro-
teinases (MMPs) are known to be crucial for the degradation of the
matrix in a Matrigel
TM invasion assay in vitro [34,35] as well as for
the extracellular matrix in vivo [36,37], we wanted to elucidate
whether MMPs were involved in FL-L1CAM-induced formation
of metastatic colonies, To this end, we determined expression and
activity of the gelatinases MMP-2 and MMP-9, well known to be
Full-Length L1CAM Promotes Metastasis
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FL-L1CAM in HT1080lacZ-K15 cells led to increased expression
of MMP-2 (Fig. 5B) and MMP-9 (Fig. 5C). Activity of MMP-2 was
markedly, activity of MMP-9 was even significantly increased in
tumour cells overexpressing FL-L1CAM in vitro (Fig. 5D and E). In
situ zymography on lung sections showed enhanced gelatinolytic
activity within metastatic foci formed by FL-L1CAM overexpress-
ing tumour cells in vivo (Fig. 5F).
FL-L1CAM, and not SV-L1CAM, was preferentially sorted
into retrograde and recycling endosomal compartments
Previous work has demonstrated that the YRSLE motif in the
cytoplasmic part of L1CAM encoded by exon 27 mediates clathrin-
dependent endocytosis of L1CAM [13]. More recently, compart-
ment-specific endosomal signalling mechanisms of internalized cell
surface receptors have been identified [41], suggesting a role of
endosomal signalling indevelopmentand progression of cancer [42].
Figure 1. Both FL-L1CAM and SV-L1CAM were expressed in benign and malignant tumours of human ovarian carcinoma patients.
Expression of FL-L1CAM (A) and SV-L1CAM mRNA (B) was analyzed in benign and malignant ovarian tumours and their peritoneal metastases. Mean
of relative target gene mRNA vs. 18S rRNA 6 SEM: A. Values obtained for FL-L1CAM; benign tumours: 1.8560.85, n=2; FIGO I: 0.7360.49, n=5; FIGO
III or FIGO IV: 5.3062.53, n=7; metastases: 2.5761.37, n=12 (p=0.664, as determined by Kruskal-Wallis One Way ANOVA on Ranks). B. Values
obtained for SV-L1CAM; benign tumours: 4.9963.99, n=2; FIGO I: 17.33610.41, n=5; FIGO III or FIGO IV: 189.13663.25, n=5; metastases:
240.21651.18, n=8 (all groups: *p=0.015, as determined by Kruskal-Wallis One Way ANOVA on Ranks and subsequent post hoc comparison using
Holm-Sidak method; pairwise comparisons (unadjusted p values): FIGO I vs. benign: p=0.903; FIGO III or FIGO IV vs. benign: p=0.084; metastases vs.
benign: *p=0.024; FIGO III/IV vs. FIGO I: *p=0.037; metastases vs. FIGO I: **p=0.005; metastases vs. FIGO III/IV: p=0.465).
doi:10.1371/journal.pone.0018989.g001
Figure 2. Expression of L1CAM splice variants was deregulated in carcinoma cells upon exposure to pro-metastatic factors. Mean FL-
L1CAM or SV-L1CAM mRNA levels 6 SEM (columns 6 bars) after incubation with pro-metastatic factors. Target gene mRNA levels were normalized to
18S rRNA levels and the means of the relative reference group without incubation with a pro-metastatic factor were set as 100%. A.1 610
5 SKOV3ip-
lacZ ovarian carcinoma cells were incubated for 48 h with or without 5 ng/ml of recombinant TGF-b1 (recTGF-b1). FL-L1CAM/Ø: 100.0%627.6%, n=9
cell pools; FL-L1CAM/recTGF-b1: 403.5%698.1%, n=9 cell pools; SV-L1CAM/Ø: 100.0%614.2%, n=9 cell pools; SV-L1CAM/recTGF-b1: 116.2%64.0%,
n=9 cell pools (FL-L1CAM, SKOV3ip-lacZ+recTGF-b1 vs. SKOV3ip-lacZ2recTGF-b1:* * p=0.005; SV-L1CAM, SKOV3ip-lacZ+recTGF-b1 vs. SKOV3ip-
lacZ2recTGF-b1: p=0.266, as determined by Wilcoxon Signed Rank test). B.1 610
5 HCT-116 colon carcinoma cells were incubated for 10 days with or
without 10 ng/ml of recombinant HGF (recHGF). FL-L1CAM/Ø: 100.0%6100.0%, n=9 cell pools; FL-L1CAM/recHGF: 673.9%6369.7%, n=9 cell pools;
SV-L1CAM/Ø: 100.0%64.6%, n=9 cell pools; SV-L1CAM/recHGF: 104.9%62.7%, n=9 cell pools (FL-L1CAM, HCT-116+recHGF vs. HCT-1162recHGF:
p=0.313; SV-L1CAM, HCT-116+recHGF vs. HCT-1162recHGF: p=0.250, as determined by Wilcoxon Signed Rank Test).
doi:10.1371/journal.pone.0018989.g002
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endocytic sorting of FL- and SV-L1CAM following antibody-
induced cell surface internalization. We revealed differential
endosomal sorting of the L1CAM variants (Fig. 6A to D). We
found a significantly higher percentage of vesicles positive for SV-
L1CAM that co-localized with GFP-LAMP1-positive lysosomes
compared to FL-L1CAM. No significant alterations were observed
for FL- or SV-L1CAM positive vesicles that co-localized with
YFP-KIF16B-positive early endosomes. However, the ratio of FL-
L1CAM-positive vesicles co-localizing with YFP-TGN38 was
Figure 3. FL-L1CAM promoted the metastatic potential of HT1080lacZ-K15 human fibrosarcoma cells. HT1080lacZ-K15 cells were
transfected with retroviruses coding for FL-L1CAM cDNA or SV-L1CAM cDNA or with an empty vector without transgene. A. Western Blot analysis of
L1CAM showed that HT1080lacZ-K15 cells did not express any L1CAM isoform endogenously, whereas expression of FL-L1CAM or SV-L1CAM was
detected after gene transfer. The two bands at 220 kDa and 200 kDa are due to differential glycosylation status of L1CAM. B. alamarBlueH
proliferation assay did not document any difference in proliferation between the different HT1080lacZ-K15 cell lines. Mean cell number 6 SEM (dots
6 bars). The mean of the 0 h value within each group was set as 1. Empty: 0 h: 1.00060.046, 24 h: 2.03960.037, 48 h: 3.45760.203, 72 h:
4.95060.401; FL-L1CAM: 0 h: 1.00060.014, 24 h: 1.96560.066, 48 h: 3.45860.101, 72 h: 4.79760.164; SV-L1CAM: 0 h: 1.00060.016, 24 h:
2.09660.112, 48 h: 3.32860.031, 72 h: 4.91860.241. C to E. 21 days after inoculation of 1610
6 of the different HT1080lacZ-K15 cells, CD1
nu/nu mice
were sacrificed, and their lungs and livers were removed. C. X-Gal staining (indigoblue foci) of removed lungs. Representative surface images are
presented (bars: 2 mm). D. Mean number of macrometastases in lungs 6 SEM (columns 6 bars). The mean of the reference group (empty) was set as
100%. Empty: 100.0%643.3%, n=6 mice; FL-L1CAM: 554.6%6324.1%, n=4 mice; SV-L1CAM: 434.0%6202.8%, n=6 mice (FL-L1CAM vs. empty:
p=0.067; SV-L1CAM vs. empty: p=0.180; SV-L1CAM vs. FL-L1CAM: p=0.610, as determined by Mann-Whitney Rank Sum test). E. Mean human
GAPDH mRNA levels 6 SEM (columns 6 bars) in lungs. GAPDH-mRNA levels were normalized to 18S rRNA levels and the mean of the reference group
(empty) was set as 100%. Empty: 100.0%648.4%, n=6 mice; FL-L1CAM: 459.1%6171.2%, n=4 mice; SV-L1CAM: 197.1%692.9%, n=6 mice (FL-
L1CAM vs. empty: p=0.067; SV-L1CAM vs. empty: p=0.485; SV-L1CAM vs. FL-L1CAM: p=0.257, as determined by Mann-Whitney Rank Sum test). F.
Mean human GAPDH mRNA levels 6 SEM (columns 6 bars) in livers. GAPDH mRNA levels were normalized to 18S rRNA levels and the mean of the
reference group (empty) was set as 100%. Empty: 100.0%656.9%, n=6 mice; FL-L1CAM: 3078.7%6999.7%, n=4 mice; SV-L1CAM: 121.5%6109.2%,
n=6 mice (FL-L1CAM vs. empty: *p=0.010; SV-L1CAM vs. empty: p=1.000; SV-L1CAM vs. FL-L1CAM: *p=0.019, as determined by Mann-Whitney
Rank Sum Test).
doi:10.1371/journal.pone.0018989.g003
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indicate that FL-L1CAM is preferentially sorted into retrograde
and recycling endosomes compared to SV-L1CAM. They further
suggest that alternative exon usage might result in differential
signal propagation from endosomal compartments.
Discussion
In the present study, we revealed for the first time the different roles
of FL-L1CAM and its splice variant in the promotion of metastasis. We
demonstrated that the full-length isoform was responsible for the pro-
metastatic effect of L1CAM, suggesting an important role of the exons
2 and/or 27 for tumour progression.
L1CAM overexpression is detected in a variety of cancers and is
known to promote tumour growth and metastasis [16,18]. Our
present findings that the expression of L1CAM was increased
during progression of human ovarian carcinomas are in line with
this evidence. Importantly, we detected that also FL-L1CAM is
expressed in ovarian tumours of advanced stage, while previous
reports emphasized the exclusive tumour-association of SV-
L1CAM [29,43]. Since FL-L1CAM and SV-L1CAM arise from
the L1CAM transcript by alternative splicing, one can suggest that
factors exist which are able to modulate alternative splicing of
L1CAM leading to predominant expression of SV-L1CAM.
However, these factors are completely unknown so far. One
reason for the neglected significance of FL-L1CAM expression
seems to be the fact that it was impossible to distinguish the two
isoforms on the protein level due to lack of specific antibodies.
Furthermore, possibly due to SV-L1CAM being seemingly
tumour-associated, nobody had so far challenged the hypothesis
that SV-L1CAM is also functionally the most important L1CAM
variant for tumour progression. The surprising finding of the
present study is that FL-L1CAM rather than SV-L1CAM is the
important determinant of metastasis. This revises the so far
prevalent notion that this full length isoform should not play a role
in carcinogenesis and tumour progression [28], as – due to its
assumed restriction to neuronal tissues [17,44] – it was thought to
be mainly associated with normal physiology or specific neuronal
disorders [17]. Importantly, our present finding shows that the FL-
L1CAM variant and not the SV-L1CAM splice variant was
inducible by exposure of tumour cells to pro-metastatic factors. It
has already been reported that the expression of L1CAM can be
induced by TGF-b1 in general [45,46]. Interestingly, in the present
study we detected a selective up-regulation of FL-L1CAM upon
exposure of SKOV3ip-lacZ human ovarian carcinoma cells to
TGF-b1and of HCT-116 human colon carcinoma cells to HGF,
which are known pro-metastatic factors [30,31]. Our study shows
that quantity is not the major determinant, as FL-L1CAM,
Figure 4. FL-L1CAM also promoted the metastatic potential of SKOV3ip-lacZ human ovarian carcinoma and L-CI.5s murine T-
lymphoma cells. SKOV3ip-lacZ (A and B) as well as L-CI.5s (C and D) cells were stably transduced with retroviruses coding for cDNA of FL-L1CAM or
SV-L1CAM or with a retroviral vector without cDNA (empty). A and B. 26 days after inoculation of 1.0610
5 of the different SKOV3ip-lacZ cells, CD1
nu/nu
mice were sacrificed and their lungs were removed. A. X-Gal staining (indigoblue foci) of removed lungs. Representative surface images are presented
(bars: 2 mm). B. Mean number of macrometastases in lungs 6 SEM (columns 6 bars). The mean of the reference group (empty) was set as 100%; n=4
mice each. Empty: 100.0%619.1%; FL-L1CAM: 187.8%610.3%; SV-L1CAM: 120.6%614.2% (all groups: **p=0.006, as determined by Kruskal-Wallis
One Way ANOVA on Ranks and subsequent post hoc comparison using Dunn’s method; pairwise comparisons (unadjusted p values): FL-L1CAM vs.
empty: **p=0.002; SV-L1CAM vs. empty: p=0.355; SV-L1CAM vs. FL-L1CAM: *p=0.011). C. and D. 7 days after inoculation of 5610
3 of the different L-
CI.5s cells, DBA/2 mice were sacrificed and their livers were removed. C. X-Gal staining (indigoblue foci) of removed livers. Representative surface
images are presented (bars: 2 mm). D. Mean number of macrometastases in livers 6 SEM (columns 6 bars). The mean of the reference group (empty)
was set as 100%. Empty: 100.0%67.5%, n=10 mice; FL-L1CAM: 131.8%612.4%, n=4 mice; SV-L1CAM: 92.6%610.3%, n=5 mice (FL-L1CAM vs.
empty: *p=0.029; SV-L1CAM vs. empty: p=0.200; SV-L1CAM vs. FL-L1CAM: *p=0.029, as determined by Mann-Whitney Rank Sum test).
doi:10.1371/journal.pone.0018989.g004
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PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18989Figure 5. FL-L1CAM over-expression correlated with increased invasive capacity, gelatinase expression and activity in vitro, and
gelatinolytic activity in vivo. HT1080lacZ-K15 cells were stably transduced with retroviruses coding for cDNA of FL-L1CAM or SV-L1CAM or with a
retroviral vector without cDNA (empty). A. Mean number of invaded cells per image section 6 SEM (columns 6 bars) for the different HT1080lacZ-K15
cells. The mean of the reference group (empty) was set as 100%; n=4. Empty: 100.0%610.6%; FL-L1CAM: 170.6%623.5%; SV-L1CAM: 54.3%65.4%
(FL-L1CAM vs. empty: p=0.057; SV-L1CAM vs. empty: **p=0.009; SV-L1CAM vs. FL-L1CAM: **p=0.003; as determined by Mann-Whitney Rank Sum
test). B . and C. Mean MMP-2 (B) and MMP-9 (C) mRNA expression levels in the different HT1080lacZ-K15 cells 6 SEM (columns 6 bars) as quantified
by qRT-PCR. The mean of the reference group (empty) was set as 100%; n=3. B. Empty: 100.0%62.7%; FL-L1CAM: 269.1%63.0%; SV-L1CAM:
150.4%637.6% (FL-L1CAM vs. empty: p=0.100; SV-L1CAM vs. empty: p=0.100; SV-L1CAM vs. FL-L1CAM: p=0.100; as determined by Mann-Whitney
Rank Sum Test). C. Empty: 100.0%645.4%; FL-L1CAM: 207.7%625.0%; SV-L1CAM: 180.7%620.9% (FL-L1CAM vs. empty: p=0.200; SV-L1CAM vs.
empty: p=0.200; SV-L1CAM vs. FL-L1CAM: p=0.400; as determined by Mann-Whitney Rank Sum Test). Mean MMP-2 (D) and MMP-9 (E) activity of the
different HT1080lacZ-K15 cells 6 SEM (columns 6 bars). The mean of the reference group (empty) was set as 100%. D. Empty: 100.0%67.3%; FL-
L1CAM: 140.4%67.9%; SV-L1CAM: 87.5%615.9%; n=3 (FL-L1CAM vs. empty: p=0.100; SV-L1CAM vs. empty: p=0.700; SV-L1CAM vs. FL-L1CAM:
p=0.100; as determined by Mann-Whitney Rank Sum test). E. Empty: 100.0%63.5%; FL-L1CAM: 124.5%63.3%; SV-L1CAM: 90.0%67.0%; n=3 (all
groups: *p=0.007, as determined by Kruskal-Wallis One Way ANOVA on Ranks and subsequent post hoc comparison using Dunn’s method; pairwise
comparisons (unadjusted p values): FL-L1CAM vs. empty: *p=0.013; SV-L1CAM vs. empty: p=0.201; SV-L1CAM vs. FL-L1CAM: **p=0.003). F. 21 days
after inoculation of 1610
6 of the different HT1080lacZ-K15 cells, CD1
nu/nu mice were sacrificed and their lungs were removed. In situ zymography was
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crucial factor in the specific process of metastatic colonization.
Thus, these data allow us to assign a metastasis-promoting
function for the previously unsuspected FL-L1CAM rather than
for the usual suspect SV-L1CAM. They further support the idea of
alternative splicing as a tightly regulated process and suggest that
marginal imbalances in the splicing homeostasis, as provoked by
pro-metastatic stimuli, are sufficient to elicit or to exacerbate
tumours [4,5,47].
In order to confirm that FL-L1CAM accounted for the
metastasis-promoting function of this adhesion molecule in vivo,
we inoculated HT1080lacZ-K15 that selectively overexpressed
either FL-L1CAM or SV-L1CAM. This cell line allows separate
functional studies for each isoform without interference through
the expression of the other variant, since it does not express any
L1CAM variant endogenously. Indeed, elevated levels of FL-
L1CAM but not of SV-L1CAM promoted experimental lung
metastasis in mice. We ruled out that this metastasis-promoting
effect simply relied on increased tumour cell proliferation, a
finding which is in accordance with previous results [48,49]. When
we up-regulated FL-L1CAM in human ovarian carcinoma and
murine T-lymphoma cells, we observed an analogous promotion
of lung (SKOV3ip-lacZ) and liver (L-CI.5s) metastasis. This means
that the FL-L1CAM-mediated pro-metastatic effect was detectable
in different metastatic secondary sites as well as with different
tumour entities (solid epithelial, solid mesenchymal, and haema-
tological malignancies), ruling out strict organ- and cell line-
specificity. Since the SV-L1CAM isoform was expressed at higher
levels than the full length isoform FL-L1CAM upon overexpres-
sion in two of the three used cell lines (HT108lacZ-K15 and L-
CI.5s), one can speculate that the increased metastatic capacity of
the FL-L1CAM isoform may be even more pronounced than that
detected in the experimental metastasis assay in vivo.
As elevated invasive potential is one driving force of metastasis
[50] and L1CAM has been shown to promote cell invasion [33], we
investigated whether FL-L1CAM caused an increase in the invasive
potential of tumour cells. Indeed, we were able to show that
overexpressionofFL-L1CAMleads toincreased invasion oftumour
cells in vitro. Cell invasion is strongly dependent on proteolytic
activity of matrix-degrading enzymes [51]. To reveal a possible link
between the FL-L1CAM-specific invasive potential and proteolytic
activity, we analyzed whether FL-L1CAM overexpression inter-
fered with the expression and activity of known metastasis-
promoting proteases. Indeed, we identified FL-L1CAM as a
positive regulator of expression and activity of MMP-2 and
MMP-9 in vitro as well as of gelatinolytic activity within lung
metastases in vivo. A link between L1CAM and the induction of
proteolytic activity has only been proposed in a wound healing
model so far [52]. A possible explanationof the exclusive capacity of
the FL-L1CAM to induce MMP gene expression may be found in
the altered molecule structure of SV-L1CAM. The lack of exons 2
and 27 leads to a deficient protein sequence in the Ig1 region and
the short cytoplasmic tail. This alteration affects not only
homophilic and heterophilic adhesions [10] and clathrin-dependent
endocytosis [13], it also interferes with signal transduction pathways
as L1CAM can induce signalling either through interaction with
othermolecules[33,53]ordirectly viaitscytoplasmictail[49,54,55].
While we here revealed the expression and increased activity of
gelatinases MMP-2 and -9 as one molecular mechanism of how
FL-L1CAM executed its pro-metastatic features, the underlying
signalling mechanism is still unknown as FL-L1CAM-associated
induction of the classical pathways like Erk, NF-kB and STAT3
was not observed (data not shown).
Previous work has demonstrated that alternative use of exon 2
affects homo- as well as heterophilic interactions of L1CAM [11],
whereas alternative use of exon 27 affects intracellular sorting
upon internalization from the plasma membrane [13]. Both
mechanisms might modify signal transduction and subsequent
gene expression patterns in cancer cells leading to the observed
differences in the metastatic potential and expression of metastasis-
associated genes. For example, homophilic interaction of L1CAM
activates Erk2 signalling leading to enhanced cell motility and
invasion of NIH-3T3 cells [56]. Furthermore, cell-cell adhesion
mediated by homophilic L1CAM interaction has been shown to
activate other signal transduction pathways including EGF
receptor signalling [57]. On the other hand, internalized but not
cell surface L1CAM was reported to co-localize with phosphor-
ylated Erk2, suggesting that endocytosis of L1CAM is required for
activation of this signalling pathway [14]. Along this line, research
on the EGF receptor indicated that signalling mechanisms of the
internalized cell surface receptor are distinct from those at the
plasma membrane, suggesting that exclusive endosomal localiza-
tion of certain signalling components is required to facilitate
effective signal propagation [58]. Our internalization experiments
in HT1080lacZ-K15 human fibrosarcoma cells provide evidence
for preferential sorting of FL-L1CAM to retrograde endosomal
compartments and preferential sorting of SV-L1CAM to lyso-
somes. Lysosomal sorting of SV-L1CAM may segregate L1CAM
from its cytosolic substrates and thereby may be important for
negative regulation of pro-proliferative and anti-apoptotic signal-
ling mediated by L1CAM. Conversely, FL-L1CAM may promote
survival and proliferation by its preferential endosomal localiza-
tion. It is therefore possible that alternative splicing of L1CAM
activates distinct signalling pathways upon internalization. This
issue requires further investigations in future studies.
Taken together, we here show that FL-L1CAM and not the highly
expressed SV-L1CAM plays a decisive role in the promotion of
metastasis and is responsible for the induction of a metastasis-
promoting phenotype in the tumour cell. This finding makes aware
that high expression of a so-called tumour-associated variant, here SV-
L1CAM, does not per se reflect its importance in tumour progression.
Materials and Methods
Acquisition of patient samples and ethics statement
Specimens from ovarian tumours and peritoneal metastases of
22 patients were obtained from the Frauenklinik und Poliklinik,
Klinikum rechts der Isar der Technischen Universita ¨t Mu ¨nchen, Germany,
and malignant primary tumours were staged according to the
present FIGO (Fe ´de ´ration Internationale de Gyne ´cologie et d’Obste ´trique)
classification [59].
The statutes of the tissue bank (version from Aug 28, 2007) and the
agreement about asservation of tissue and blood samples for analysis in
diagnostics, science and education (version from Jun 19, 2007) regarding
the administration of the tissue bank at the Institut fu ¨r Allgemeine
Pathologie und Pathologische Anatomie, Klinikum rechts der Isar der
Technischen Universita ¨t Mu ¨nchen, Germany, were approved by the
ethics committee of the medical faculty of the Technische Universita ¨t
Mu ¨nchen. All patients had signed informed consent for the
participation to our scientific study.
performed on cryo-sections of lungs bearing metastases of the different HT1080lacZ-K15 cells. Representative images are presented (bars: 50 mm;
upper row (green signal): degraded DQ-gelatine; lower row (blue signal): DAPI counter-staining).
doi:10.1371/journal.pone.0018989.g005
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293T, HCT-116 [60], L-CI.5s [61], L-CI.5s [62], and
SKOV3ip-lacZ cells [25] were cultured as described previously.
Human FL-L1CAM cDNA (NM_000425) was obtained by
HindIII and XhoI digestion of L1a-pcDNA3 (obtained from Vance
Lemmon, Laboratory of Axon Growth and Guidance, University
of Miami, USA) and subcloned HindIII/XhoI in the HindIII and
XhoI site of pBluescript-KS(+) (Clontech, Saint-Germain-en-Laye,
Figure 6. Differential endosomal sorting of FL-L1CAM compared to SV-L1CAM in HT1080lacZ-K15 human fibrosarcoma cells. A.
HT1080lacZ-K15 cells overexpressing FL-L1CAM before and after antibody-induced internalization. B.a n dC. HT1080lacZ-K15 cells 60 min chased at 37uC
co-expressing FL-L1CAM or SV-L1CAM together with fluorophore-tagged LAMP1, KIF16B, or TGN38. Arrows indicate internalized L1CAM in selected
vesicles that co-localized with compartment markers (Scale bars: 10 mm( A to C)). D. Relative distribution of L1CAM-labeled vesicles in lysosomes (GFP-
LAMP1: SV-L1CAM: 24.0%64.2% SEM; FL-L1CAM: 18.664.0% SEM; *p=0.022,n=30 each), early endosomes (YFP-KIF16B: SV-L1CAM: 43.3%65.8% SEM;
FL-L1CAM: 53.4%65.1% SEM; p=0.194, n=30 each), retrograde and recycling endosomes (YFP-TGN38: SV-L1CAM: 35.5%66.3% SEM; FL-L1CAM:
54.7%65.2% SEM; **p=0.002,n=20 each) Data was calculated from three (FL- or SV-L1CAM+GFP-LAMP1, n=30 each) or two independent experiments
(FL-orSV-L1CAM+YFP-TGN38, n=20each) and displayed as means6 SEM (columns6 bars),p values weredetermined byMann-WhitneyRank Sum Test.
doi:10.1371/journal.pone.0018989.g006
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was obtained by NotI and XhoI digestion and cloned BamHI/blunt
in the NotI and BamHI site of pQCXIH/P vectors (Clontech,
Saint-Germain-en-Laye, France). Human SV-L1CAM cDNA
(NM_001143963) was obtained by NotI and XbaI digestion of
L1D(2,27)-pcDNA3 (obtained from Ulrich H. Weidle, Division
Pharma, Roche Diagnostics GmbH, Penzberg, Germany) and cloned
PacI/blunt in the NotI and PacI site of pQCXIH/P. Recombinant
retroviruses were generated by transient transfection of 293T cells
with 10 mg pHIT60 [63], 10 mg pHCMV-G [64] and 10 mgo f
pQCXIH/P-huFL-L1CAM, or pQCXIH/P-SV-L1CAM, respec-
tively. Retroviral transduction was performed as described
previously [61]. Transduction of adherent cells was performed
using viral supernatant and transduction of the suspension cell line
L-CI.5s was performed by co-culture with virus-producing 293T
cells for 48 h.
Experimental metastasis assays
Ethics statement. All animal experiments were performed in
compliance with the guidelines of the Tierschutzgesetz des Freistaates
Bayern and approved by the Regierung von Oberbayern (permission
number: 55.2-1-54-2531-69-05) and all efforts were made to
minimize suffering.
Execution. 1.0610
5 SKOV3ip-lacZ or 1610
6 HT1080lacZ-
K15 cells were inoculated into the tail vein of pathogen-free,
athymic, female CD1
nu/nu mice (Charles River, Sulzfeld,
Germany). 5610
3 L-CI.5s were analogously inoculated into
pathogen-free, syngeneic, female DBA/2 mice (Charles River,
Sulzfeld, Germany). Mice were sacrificed 7 d (L-CI.5s), 21 d
(HT1080lacZ-K15), or 26 d (SKOV3ip-lacZ) after tumour cell
inoculation. For quantification of macrometastatic foci, livers or
lungs were stained with X-Gal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) (Fermentas, St. Leon-Rot, Germany) as
described previously [62]. All foci on the surface of the left lung
lobe and foci .0.2 mm on the surface of the median liver lobes
were counted.
In vitro assays
For incubation with recHGF or recTGF-b1 (both from
PromoCell, Heidelberg, Germany), 1610
5 cells were seeded on
6 well plates. HCT-116 cells were treated daily with 10 ng/ml
recHGF for 10 d. Medium was replaced every second day and
confluent cells were trypsinized and transferred to 6 cm dishes.
Incubation of SKOV3ip-lacZ cells was done for 48 h after addition
of 5 ng/ml recTGF-b1 on the day after seeding. For analysis of cell
viability/proliferation, 2610
3 cells/well were seeded in 96 well
plates, and the number of living cells was quantified 24 h, 48 h
and 72 h after seeding using the alamarBlueH proliferation assay
(Invitrogen, Darmstadt, Germany). Analysis was performed
according to the manufacturer’s protocol. Invasion assays were
performed using Costar Transwell Permeable Supports with 8 mm
pore size coated with Matrigel
TM (Corning Inc., Corning, NY,
USA). 5610
4 HT1080lacZ-K15 cells were seeded in serum-free
media. Media containing 10% FCS was used as chemoattractant
added to the bottom chamber of 24 well plates. After an
incubation time of 24 h at 37uC, non-invasive cells were removed
using a cotton stick and invaded cells were fixed using Diff-Quik
solution (Dade Behring, Marburg, Germany) and stained using
DAPI. For detection of active MMP-2 and MMP-9 in cell culture
supernatants, 1.5610
6 HT1080lacZ-K15 or 1.3610
6 SKOV3ip-
lacZ cells were seeded in a 10 cm dish. After 24 h medium was
removed, cells were washed twice with PBS, and incubated with
FCS-free medium. Another 48 h later, supernatant was collected
and MMP-2 and MMP-9 activities were quantified using either
the MMP-2 or MMP-9 Biotrak activity assay system (GE
Healthcare, Buckinghamshire, UK) according to the manufactur-
er’s instructions.
RNA isolation, reverse transcription, and qRT-PCR
According to the manufactures’ protocols, RNA isolation from
cell lines was performed using TRI-Reagent (Sigma-Aldrich,
Taufkirchen, Germany) and RNA isolation from murine lung and
liver tissues as well as from human primary tumours and
metastases was done with RNeasy Midi Kit (Qiagen, Hilden,
Germany) after harvesting the snap-frozen tissues. Reverse
transcription and qRT-PCR were performed as described
previously [65]. Assays were obtained from Applied Biosystems,
Darmstadt, Germany. The inventoried primer-probe-set
(Hs01109766_g1) for quantification of FL-L1CAM mRNA
transcription detected the exon 26/27 boundary, which is only
present in FL-L1CAM (RefSeq: NM_000425.3), whereas the assay
ordered on demand for analysis of SV-L1CAM mRNA transcrip-
tion detected the exon 26/28 boundary (RefSeq: NM_001143963;
Assay ID: huL1e26-28-ex26). Detection of absence of exon 27 was
sufficient to recognize SV-L1CAM, which is lacking the exons 2
and 27, as splicing of one exon is described to be accompanied by
excision of the other exon [66]. For quantification of human
MMP-2 and MMP-9 expression, MMP-2 (Hs00234422_m1) and
MMP-9 (Hs00234579_m1) TaqMan Gene Expression Assays
were used. Human GAPDH was quantified using human GAPD
(GAPDH, 4352934E; RefSeq: NM_002046.3). Data was normal-
ized to human 18S rRNA (4319413E, RefSeq: X03205.1).
Western blot analysis and in situ zymography
Protein isolation, purification, and quantification as well as
Western Blot analysis were performed as described previously
[65]. The monoclonal antibody L1-11A to the ectodomain of
human L1CAM (subclone of UJ 127.11) was used for Western Blot
analysis of L1CAM as described before [67]. For in situ
zymography, metastases-bearing lung samples were embedded in
Tissue-TekH O.C.T
TM Compound (Sakura Finetek, Staufen,
Germany) and shock-frozen on dry-ice. In situ zymography was
performed as reported previously [68].
L1CAM internalization assay
HT1080lacZ-K15 cells were grown on Poly-D-Lysine (Sigma)
coated glass cover slips in DMEM/8% FCS. Cells were
transfected by RotifectPlus (Roth, Karlsruhe, Germany) with
plasmids encoding either FL-L1CAM or SV-L1CAM along with
constructs encoding for GFP-LAMP1 [69], KIF16B-YFP [70] or
YFP-TGN38 [71,72]. Twenty hours after co-transfection, cells
were live-stained on ice for 45 min with a polyclonal antibody
specific for the extracellular part of human L1CAM [73], which
induces L1CAM internalization. Cells were chased for 60 min at
37uC and processed for secondary antibody incubation using Cy3-
conjugated anti-rabbit IgG (Jackson ImmunoResearch, West
Grove, PA, USA) and confocal microscopy. As a control, we
analyzed cells expressing either FL-L1CAM or SV-L1CAM before
chase at 37uC, confirming that the plasma membrane of live-
stained cells remained intact and that L1CAM-immunolabelling
was only observed at the cell surface of transfected cells under
these conditions. Double-transfected cells displaying Cy3-labeled
L1CAM and low level expression of fluorophore-tagged plasmids
were randomly selected and scanned with a LSM 510 confocal
microscope (Zeiss, Jena, Germany) using a 636 objective and
appropriate filters. Eight confocal middle sections of 0.38 mm were
acquired from individual cells. For quantification, xy-sections were
superimposed as z-stacks. The number of the individual
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percentage of vesicles co-localizing with the fluorophore-tagged
marker protein calculated.
Statistical analysis
Normal distribution of data was tested using the Kolmogorov-
Smirnov test and equal variance was tested using Levene-Median
test. Three or more group experiments with non-normally
distributed data were statistically analyzed by Kruskal-Wallis
Analysis of Variance (ANOVA) on Ranks (Fig. 1A) and
subsequent post hoc comparison by applying either the Holm-
Sidak or Dunn’s method (all pairwise comparison; Fig. 1B, 4B, and
5E). Two group experiments with non-normally distributed data
was analyzed by Mann-Whitney Rank Sum test (Fig. 3E, 3F, 4D,
5A to 5D, and 6D) and Wilcoxon Signed Rank test (in the case of
two group comparisons of the same individuals before and after a
single treatment; Fig. 2A and 2B). Statistic significance was
indicated according to the Michelin Guide scale: p,0.05 (*,
significant), p,0.01 (**, highly significant), and p,0.001 (***,
extremely significant). All statistical analyses were performed using
SigmaStat for Windows version 3.00 software (SPSS Inc.).
Supporting Information
Figure S1 L1CAM expression and proliferation analysis
of transduced SKOV3ip-lacZ cells. SKOV3ip-lacZ cells were
transduced with FL- or SV-L1CAM cDNA or with an empty
vector. A. Western Blot analysis of L1CAM showed increased
expression of L1CAM variants after gene transfer. The two bands
at 220 kDa and 200 kDa are due to differential glycosylation
status of L1CAM. B. Proliferation was unchanged after gene
transfer. Data are displayed as mean cell number 6 SEM (dots 6
bars). The mean of the 0 h value within each group was set as 1.
Empty: 0 h: 1.00060.014, 24 h: 1.73060.021, 48 h: 3.0906
0.033, 72 h: 4.48260.188; FL-L1CAM: 0 h: 1.00060.040, 24 h:
1.60460.039, 48 h: 2.75060.070, 72 h: 4.15860.154; SV-
L1CAM: 0 h: 1.00060.012, 24 h: 1.71860.034, 48 h: 3.0346
0.079, 72 h: 4.59860.166.
(TIF)
Figure S2 L1CAM expression and proliferation analysis
of transduced L-CI.5s cells. L-CI.5s cells were transduced
with FL- or SV-L1CAM cDNA or with an empty vector. A.
Western Blot analysis of L1CAM showed increased expression of
L1CAM variants after gene transfer. The two bands at 220 kDa
and 200 kDa are due to differential glycosylation status of
L1CAM. B. Proliferation was unchanged after gene transfer.
Data are displayed as mean cell number 6 SEM (dots 6 bars). The
mean of the 0 h value within each group was set as 1. Empty: 0 h:
1.00060.028, 24 h: 2.76160.126, 48 h: 7.14160.838, 72 h:
11.94160.520; FL-L1CAM: 0 h: 1.00060.026, 24 h: 2.4796
0.166, 48 h: 7.02860.115, 72 h: 11.07160.576; SV-L1CAM: 0 h:
1.00060.065, 24 h: 2.77860.214, 48 h: 7.40660.138, 72 h:
12.458plusmn;0.387.
(TIF)
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